Literature DB >> 9266803

A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity.

A M Hissink1, B Van Ommen, J Krüse, P J Van Bladeren.   

Abstract

A physiologically based pharmacokinetic (PB-PK) model was developed for 1,2-dichlorobenzene (1,2-DCB) for the rat. This model was adjusted for the human situation, using human in vitro parameters, including a Vmax and Km determined with human microsomes. For comparison, the Vmax and Km values from the rat were scaled allometrically to the human case. The model was used in two ways: (1) Acute hepatotoxicity was related to the amount of reactive metabolites (epoxides) formed in vitro. For rats, the hepatic concentration of epoxide metabolites in vivo after exposure to a toxic dose level (250 mg/kg bw) was predicted using in vitro parameters. For man, the dose level needed to obtain the same toxic liver concentration of reactive metabolites as in rat was predicted, assuming a concentration-effect relationship in the liver. It could be concluded that this concentration is not reached, even after induction of the oxidation step, due to saturation of metabolism and a concomitant accumulation of 1,2-DCB in fat. (2) Hepatotoxicity was related to depletion of glutathione (GSH) in the liver. In the model, the consumption of hepatic GSH by metabolism (based on in vivo and in vitro data) and normal turnover was described. In vivo validation was conducted by comparing the predictions of the model with the results of a GSH depletion study performed at two dose levels (50 and 250 mg/kg bw). Subsequently, the GSH consumption by 1,2-DCB metabolites was estimated for man using human in vitro metabolic data. GSH turnover in human liver was assumed to be the same as that in rat. It appeared that at a dose level of 250 mg/kg, hepatic GSH was completely depleted after 10 hr for man, whereas for the rat a maximum depletion of 75% was predicted, after 15 hr. The presented model provides a quantitative tool for evaluating human risk for two different toxicity scenarios, namely covalent binding of reactive metabolites and depletion of GSH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266803     DOI: 10.1006/taap.1997.8184

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  3 in total

1.  A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans.

Authors:  Niek C A van de Pas; Ruud A Woutersen; Ben van Ommen; Ivonne M C M Rietjens; Albert A de Graaf
Journal:  J Lipid Res       Date:  2012-09-29       Impact factor: 5.922

2.  Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats.

Authors:  Ans Punt; Alicia Paini; Marelle G Boersma; Andreas P Freidig; Thierry Delatour; Gabriele Scholz; Benoît Schilter; Peter J van Bladeren; Ivonne M C M Rietjens
Journal:  Toxicol Sci       Date:  2009-05-15       Impact factor: 4.849

3.  Gene expression response in target organ and whole blood varies as a function of target organ injury phenotype.

Authors:  Edward K Lobenhofer; J Todd Auman; Pamela E Blackshear; Gary A Boorman; Pierre R Bushel; Michael L Cunningham; Jennifer M Fostel; Kevin Gerrish; Alexandra N Heinloth; Richard D Irwin; David E Malarkey; B Alex Merrick; Stella O Sieber; Charles J Tucker; Sandra M Ward; Ralph E Wilson; Patrick Hurban; Raymond W Tennant; Richard S Paules
Journal:  Genome Biol       Date:  2008-06-20       Impact factor: 13.583

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.